DWSH

AdvisorShares Dorsey Wright Short ETF

Bernstein raised its price target on Campbell's to $39 from $38 and noted that the company appears to be taking the right steps to revitalize the portfolio, investing in brand support and innovation.

Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said.

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Truist, however, kept a ‘Buy’ rating on the shares.

Wells’ new price target of $50 implies nearly 208% upside potential from the stock’s closing price on Wednesday.

JPMorgan upgraded Sarepta to ‘Neutral’ from ‘Underweight’ with a $24 price target.

A company spokesperson told Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.

While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.